Hubro Bioscience

Hubro Bioscience is a privately held biotech company devoted to the development and commercialisation of novel proprietary diagnostic tools for early detection and monitoring of cancer biomarkers in liquid biopsies.

Company highlights

Technology for early detection of biomarkers associated with microsatellite instability (MSI) cancers in liquid biopsies
Easy to use diagnostic tests targeting cancer specific frameshift mutations resulting from MSI
Proprietary PCR primers for specific detection of selected early occurring frameshift mutations
Test target panel providing high biomarker coverage of MSI cancers
Hubro has a strong focus on intellectual property rights
Strong, experienced management team

Hubro is the Norwegian name for the Eurasian eagle owl – known for its extremely sharp night vision and its ability to see what most others cannot. In our research, we find that ability inspiring.”

– Jon Amund Eriksen, CEO Hubro Bioscience

Immunotherapy market

The Hubro diagnostic tests identifies MSI cancer associated biomarkers and as such the patient population who would benefit from immunotherapy gives a good indication of the market for the diagnostic tests.

The global cancer immunotherapy market is expected to reach $111,098.5 million by 2025.

Hollingsworth, R. E. & Jansen, K. NPJ vaccines 4, 7, doi:10.1038/s41541-019-0103-y (2019).

Experienced team

The Company has a highly experienced international management and operational team, an extensive network of industrial and academic partners to optimise and leverage the development of its novel technology.

Menu

Hubro Bioscience

Company highlights

Hubro is the Norwegian name for the Eurasian eagle owl – known for its extremely sharp night vision and its ability to see what most others cannot. In our research, we find that ability inspiring.”

Immunotherapy market

Experienced team

This website uses cookies to ensure you get the best experience on our website.